Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00889382
Other study ID # OSI-906-202
Secondary ID 2009-010319-34
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date August 5, 2009
Est. completion date August 25, 2014

Study information

Verified date November 2019
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.


Description:

The phase 1 dose escalation portion will establish the maximum tolerated dose (MTD) in patients with advanced solid tumors. Once the recommended phase 2 dose (RP2D) is established for both schedules, the phase 2 study will begin. Patients with relapsed/recurrent epithelial ovarian cancer will be randomized 1:1:1 to 3 treatment groups.


Recruitment information / eligibility

Status Completed
Enrollment 152
Est. completion date August 25, 2014
Est. primary completion date August 1, 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed epithelial ovarian carcinoma Patients with fallopian or peritoneal cancer will also be eligible

- Patients with any solid tumor that may be treated with weekly paclitaxel will be eligible for the phase 1 portion

- For the phase 2 portion, patients must have elevated CA125 levels evaluable/assessable according to Gynecological Cancer Intergroup (GCIG) criteria (ie, > 70 U/mL) documented by 2 measurements at least 1 week apart

- Patients must have radiologically confirmed progressive disease by RECIST v1.1 criteria within 6 months prior to randomization. (patients must have measurable disease according to RECIST v1.1)

- Eastern Cooperative Oncology Group (ECOG) performance status(PS) 0 -1

- Predicted life expectancy = 12 weeks

- Patients may have had prior therapy, providing the following conditions are met:

- Chemotherapy: Prior chemotherapy must have been completed at least 3 weeks prior to study enrollment (6 weeks for mitomycin C, nitrosoureas or high-dose carboplatin [= 600 mg/m²]and 4 weeks for investigational drugs

1. Patient should have recovered from any drug-related toxicities (with the exception of grade 1 neuropathy and or alopecia)

2. Phase 1: While there is no limit on the number of prior regimens for patients entered into the phase 1 portion, any prior taxane therapy must have been administered on a 3 week schedule

3. Phase 2: Patients must have received prior chemotherapy, which must have contained a platinum and a taxanes at some point. Any prior taxanes therapy must have been administered on a 3 week schedule. A maximum of 2 prior chemotherapy regimens are permitted. Patients must be refractory radiologically confirmed by computerized tomography (CT) scan progressive disease (PD) during chemotherapy) or resistant (radiologically confirmed by CT scan PD within six months of completing chemotherapy) to their last platinum-containing chemotherapy regimen

- Radiation: Patients may have had prior radiation therapy provided they have recovered from the acute, toxic effects of radiotherapy prior to registration/randomization. Radiated lesions cannot be chosen as the target lesions

a. A minimum of 21 days must have elapsed between the end of radiotherapy and registration/randomization into the study unless the radiation affected less than 25% of bone marrow

- Surgery: Previous surgery is permitted provided that adequate wound healing has occurred prior to registration/randomization

- Fasting glucose = 150 mg/dL (8.3 mmol/L)

- Adequate hematopoietic, hepatic, and renal function defined as follows:

- Neutrophil count = 1.5 x 10 ^9 /L and platelet count > = 100 x 10^9/L;

- Bilirubin = 1.5 x Upper Limit of Normal (ULN);

- AST and/or ALT = 2.5 x ULN or < = 5 x ULN if patient has documented liver metastases; and

- Serum creatinine = 1.5 x ULN

- Female patient must be either:

- Of non childbearing potential:

1. post-menopausal (defined as at least 1 year without any menses) prior to Screening, or

2. documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening)

- Or, if of childbearing potential:

1. must have a negative urine pregnancy test at Screening, and

2. must use two forms of birth control (one of which must be a barrier method) starting at Screening and throughout the study period and for 28 days [or 5 half lives, whichever is longer] after final study drug administration

- Female patient must not be breastfeeding at Screening or during the study period and for 28 days [or 5 half lives of the study drug whichever is longer] after final study drug administration

- Female patient must not donate ova starting at Screening and throughout the study period and for 28 days [or 5 half lives of the study drug whichever is longer] after final study drug administration

- Patients must provide verbal and written informed consent to participate in the study

Exclusion Criteria:

- Diabetes mellitus currently requiring medication (eg, insulin or oral hypoglycemics)

- During the phase 2 portion, patients with histology of abdominal adenocarcinoma of unknown origin or a diagnosis of a borderline ovarian tumor

- Previous or concurrent malignancies (excluding curatively treated basal or squamous cell carcinoma of the skin or cervical carcinoma in situ) unless the patient has been in remission for at least 3 years

- History of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac diseases includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)

- History of cerebrovascular accident (CVA) within 6 months prior to registration/randomization or that is not stable

- Prior therapy with an insulin-like growth factor (IGF-1R) inhibitor

- Use of drugs that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing

- Known or prior hypersensitivity to taxanes in spite of premedication or drugs containing Cremophor

- Gastro-intestinal abnormalities, including bowel obstruction, inability to take oral medication, requirement for intravenous (IV) alimentation,active peptic ulcer or prior surgical procedures or bowel resection affecting absorption

- Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to registration/randomization) that would impair the ability of the patient to receive protocol treatment

- History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent

- Pregnancy or breast-feeding

- Symptomatic brain metastases that are not stable, require steroids, are potentially life threatening, or that have required radiation within 28 days prior to registration/randomization

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug

- History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (= grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded. Patients with mean QTcF interval = 450 msec at screening are excluded

- Use of drugs that have a known risk of causing Torsade de Pointes (TdP) or that that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing are prohibited

- Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent CYP1A2 inhibitors/inducers are not excluded

- Participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half lives whichever is longer, prior to the initiation of Screening or during the course of the study

Study Design


Intervention

Drug:
OSI-906
Administered orally
Paclitaxel
Administered intravenously

Locations

Country Name City State
Australia St. John of God Hospital, Bunbury Bunbury Western Australia
Australia Frankston Hospital Frankston Victoria
Australia Launceston General Hospital Launceston Tasmania
Australia Royal Adelaide Hospital North Terrace South Australia
Australia Sir Charles Gairdner Hospital Perth Western Australia
Australia Mater Adult Hospital South Brisbane Queensland
Australia St. John of Gog Hospital, Subiaco Subiaco Western Australia
Australia WestMead Hospital WestMead New South Wales
Australia Border Medical Oncology Wodonga Victoria
Canada Juravinski Cancer Center Hamilton Ontario
Canada McGill University Montreal Quebec
Canada Princess Margaret Hospital Toronto Ontario
Czechia University Hospital Hradec Kralove Kralove
Czechia University Hospital Ostrava Ostrava- Poruba
Czechia General University Hospital, Department of Obstetrics and Gynecology Prague
Italy Universitaria di Bologna Policlinico Bologna
Italy Ospedale di Carpi, AUSL di Modena Carpi
Italy Instituto Europeo di Oncologia Milan
Italy Oncology IDI- IRCSS Roma
Poland III Oddzial Onkologii Ginekologicznej Lublin
Poland Klinika Onkologii AM w Poznaniu Poznan
Poland Oddzial Radioterapii Poznan
Romania Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia de Oncologie Medicala Cluj Napoca
Romania Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia Radiologie Cluj Napoca
Romania Oncology Medical Centre SCM Iasi
Romania Clinical Caunty Hospital Mures Mures
Russian Federation Central Clinical Hospital Moscow
Russian Federation Moscow City Oncology Hospital Moscow
Russian Federation State Institution Medical Radiology Scientific Center Obninsk
Russian Federation Sity Clinical Oncology St. Petersburg
Switzerland Ospedale San Giovanni Bellinzona
United Kingdom Royal Marsden Hospital London
United Kingdom University College Hospital London
United Kingdom The Christie NHS Foundation Trust Manchester
United Kingdom Mount Vernon Cancer Center Northwood
United Kingdom Churchill Hospital Oxford
United Kingdom Drug Development Unit Royal Mardsen NHS Foundation Trust Sutton Surrey
United Kingdom Christie NHS Foundation Trust Withington
United States Blumenthal Cancer Center - Main Charlotte North Carolina
United States Duke University Medical Center Durham North Carolina
United States Horizon Oncology Center Lafayette Indiana
United States Morristown Memorial Hospital Morristown New Jersey
United States Ochsner Clinic Foundation New Orleans Louisiana
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Department of Obstetrics and Gynecology, University of California, Irvine Orange California
United States Mayo Clinic Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Inc

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Czechia,  Italy,  Poland,  Romania,  Russian Federation,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) Primary outcome measure for Phase 1 portion 28 days
Primary Progression Free Survival (PFS) Primary outcome measure for the Phase 2 portion; The time from the date of randomization until date of radiographic disease progression per RECIST v1.1 or until death due to any cause 36 months
Secondary Objective Response Rate (ORR) The proportion of patients with a confirmed response of Complete Response (CR) or Partial Response (PR) per RECEIST v1.1 36 months
Secondary Cancer Antigen 125 (CA125) Response Rate Response Rate is defined as at least 50% reduction in serum CA-125 levels from pretreatment levels; Response rate is the proportion of patients with a CA-125 response among evaluable patients 36 months
Secondary Duration of Response (DOR) The time from the date of the first documented radiographic response (CR/PR) to first documented radiographic progression or death due to underlying cancer 36 months
Secondary Duration of CA-125 Response (CA-125 DOR) The time from the date of the first documented CA-125 response to the date of CA-125 progression 36 months
Secondary Overall Survival (OS) The time from the date of randomization until the documented date of death 36 months
Secondary Safety assessed via physician exam, vital signs, clinical laboratory tests, electrocardiograms (ECG), and adverse events 36 months
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2